Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck

Keil, F, Selzer, E, Berghold, A, Reinisch, S, de Vries, A, Greil, R, Bachtiary, B, Tinchon, C, Anderhuber, W, Burian, M, Kasparek, AK, Elsasser, W, Kainz, H, Riedl, R, Kapp, K, Kopp, M, Kornek, G ONCOL RES TREAT. 2014, 37: 273-273. Ebenfalls in Pubmed gefunden: Eur J Cancer. 2013 Jan,49(2):352-9. doi: 10.1016/j.ejca.2012.08.004. Epub 2012 Sep 14.

INTERIM RESULTS FROM A PHASE IIA STUDY OF THE ANTI-CXCL12 SPIEGELMER OLAPTESED PEGOL (NOX-A12) IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA

Ludwig, H, Weisel, K, Petrucci, MT, Leleu, X, Cafro, AM, Kropff, M, Greil, R, Zojer, N, Dummler, T, Kruschinski, A, Riecke, K, Foa, R, Yakoub-Agha, I, Engelhardt, M HAEMATOLOGICA. 2014, 99: 115-116.

AN INTERNATIONAL, MULTICENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF NEUTROPENIA IN PATIENTS BEING TREATED WITH LENALIDOMIDE plus DEXAMETHASONE FOR RELAPSED OR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RR-MM)

Leleu, X, Terpos, E, Sanz, RG, Cooney, J, OxxxGorman, P, Minarik, J, Greil, R, Williams, C, Gray, D, Szabo, Z HAEMATOLOGICA. 2014, 99: 368-368.

A PHASE II STUDY OF RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF THE MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT LYMPHOMA)

Raderer, M, Kiesewetter, B, Willenbacher, W, Neumeister, P, Fridrik, M, Greil, R HAEMATOLOGICA. 2014, 99: 226-226.

Malignant Lymphoblasts in T Cell Acute Lymphoblastic Leukemia Express High Levels of Kv1.3

Groessinger, E, Weiss, L, Chen, MY, Wulff, H, Greil, R, Kerschbaum, H BIOPHYS J. 2014, 106(2): 551A-551A.

Bone-Targeted Therapy in Metastatic Breast Cancer – All Well-Established Knowledge?

Gampenrieder, SP, Rinnerthaler, G, Greil, R Breast Care (Basel). 2014 Oct,9(5):323-30. doi: 10.1159/000368710.

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.

Ludwig H, Kasparu H, Leitgeb C, Rauch E, Linkesch W, Zojer N, Greil R, Seebacher A, Pour L, WeiГџmann A, Adam Z. Blood. 2014 Feb 13,123(7):985-91. doi: 10.1182/blood-2013-08-521468. Epub 2013 Nov 13.

Overcoming resistance against HER2-targeting agents in fifth-line therapy: is there still a place for bevacizumab in HER2+ breast cancer?

Huemer F, Gampenrieder SP, Schlattau A, Greil R. Clin Breast Cancer. 2014 Feb,14(1):e17-20. doi: 10.1016/j.clbc.2013.09.009. Epub 2013 Sep 28.

Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review.

Hohla F, Hopfinger G, Romeder F, Rinnerthaler G, Bezan A, Stättner S, Hauser-Kronberger C, Ulmer H, Greil R. Int J Oncol. 2014 Jan,44(1):319-26. doi: 10.3892/ijo.2013.2176. Epub 2013 Nov 15.

Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz.

Geretti AM, Conibear T, Hill A, Johnson JA, Tambuyzer L, Thys K, Vingerhoets J, Van Delft Y J Antimicrob Chemother. 2014 Apr,69(4):1090-7. doi: 10.1093/jac/dkt474. Epub 2013 Nov 27.